We found that the NOD2 agonist L18-MDP activated CLL-patient monocytes, promoting the production of cytokines and an increase in the expression of FcγRs both at the transcript and protein levels. The gene discussed is NOD2; the disease is B-cell chronic lymphocytic leukemia.